Presentation Stock market days at Aktiespararna
June, 2025
Presenter:
Martin Åmark, CEO
Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.
We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.
We develop biosimilars in treatment of macular degeneration (Xlucane™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion
June, 2025
Presenter:
Martin Åmark, CEO
31 Mar 2026
Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States
31 Mar 2026
Xbrane has released the company’s 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.
13 Feb 2026
Invitation to presentation of Xbrane Biopharma’s Year-end report 2025 on February 20, 2026
24 Nov 2025
Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution